



## Comorbidities among overweight and obese adult patients seen at the General Outpatient Clinic of a Tertiary Hospital, South-South Nigeria

Kalu, Nnenna Okore Ama<sup>1</sup>, Udoh, Sunday Bassey<sup>1</sup>, Morgan, Uduak-obong Morgan<sup>1</sup>, Dianabasi Eduwem<sup>2</sup>

<sup>1</sup>Department of Family Medicine, University of Uyo Teaching Hospital, Uyo, Akwa Ibom State, Nigeria

<sup>2</sup>Department of Radiology, University of Uyo/University of Uyo Teaching Hospital, Uyo, Nigeria

### Abstract

**Background:** Overweight and obesity are major global health concerns, associated with significant morbidity and mortality. They are key risk factors for numerous non-communicable diseases (NCDs), including hypertension, diabetes mellitus, dyslipidemia, osteoarthritis, coronary heart disease, stroke, and certain cancers. This study aimed to identify the common comorbidities associated with overweight and obesity among adult patients attending the General Outpatient Clinic of the University of Uyo Teaching Hospital, Uyo, Nigeria.

**Methods:** A cross-sectional study was conducted involving 385 overweight and obese adults aged 18–60 years. Data were collected using semi-structured questionnaires. Anthropometric measurements and laboratory investigations (fasting blood glucose and lipid profile) were obtained. Data analysis was performed using SPSS version 17.0.

**Results:** Of the 385 questionnaires distributed, 380 were fully completed and analyzed (response rate: 98.7%). The identified comorbidities associated with overweight and obesity, in descending order, were: abnormal LDL (66.3%), hypertension (58.2%), hypercholesterolemia (52.6%), joint arthropathies (46.8%), erectile dysfunction (32.4%), fertility problems (30.3%), raised triglycerides (26.6%), diabetes mellitus (12.4%), and abnormal HDL (3.9%). Only osteoarthritis/arthropathies showed a statistically significant association with overweight/obesity ( $\chi^2 = 4.901$ ,  $p = 0.03$ ).

**Conclusion:** Osteoarthritis/arthropathy was the identified comorbidity significantly associated with overweight and obesity in this population. Public health efforts should promote healthier diets and active lifestyles to prevent obesity-related comorbidities.

Keywords: Overweight, Obesity, Comorbidity, Uyo, Nigeria

### Introduction

Overweight is defined as having excess body fat relative to optimal health, a condition prevalent in settings with abundant food and sedentary lifestyles.<sup>1,2</sup> Obesity, a more severe form of excess adiposity, is recognized as a disease that adversely affects health, reducing life expectancy and increasing the risk of various health problems.<sup>1-3</sup> It typically results from a chronic energy imbalance-where caloric intake exceeds expenditure.<sup>3</sup> While traditionally attributed to behavioral factors, evidence now underscores a significant genetic predisposition, with obesity emerging from complex interactions between multiple

#### Corresponding Author:

**Dr. Morgan, Uduak-obong Morgan**

Department of Family Medicine, University of Uyo Teaching Hospital, Uyo, Akwa Ibom State, Nigeria.

[uduakobongmorgan@uniuyo.edu.ng](mailto:uduakobongmorgan@uniuyo.edu.ng)

DOI: 10.61386/imj.v19i2.1055

genes and environmental influences.<sup>1</sup>

Overweight and obesity are major public health challenges, contributing substantially to global morbidity and mortality.<sup>1-4</sup> They are established risk factors for numerous NCDs, including hypertension, type 2 diabetes mellitus, dyslipidemia, osteoarthritis, coronary heart disease,

stroke, depression, respiratory disorders, cancers, and metabolic syndrome.<sup>3</sup> Key drivers of this epidemic include dietary shifts, tobacco use, excessive alcohol consumption, physical inactivity, rural-to-urban migration, and fetal malnutrition.<sup>2,5</sup>

The World Health Organization (WHO) and the U.S. National Institutes of Health (NIH) classify overweight and obesity primarily using body mass index (BMI). For most ethnic groups, a BMI of  $\geq 25$  kg/m<sup>2</sup> defines overweight, and  $\geq 30$  kg/m<sup>2</sup> defines obesity.<sup>2,6</sup> Other assessment tools include waist circumference, waist-hip ratio, skinfold thickness, bioelectrical impedance, and dual-energy X-ray absorptiometry.<sup>2,6-8</sup>

BMI remains the most widely used anthropometric index due to its strong correlation with body fat and validated association with obesity-related morbidities such as hypertension, dysglycemia, and dyslipidemia.<sup>9</sup> Obesity is further stratified into classes reflecting escalating health risks: Class I (30.0–34.9 kg/m<sup>2</sup>), Class II (35.0–39.9 kg/m<sup>2</sup>), and Class III ( $\geq 40$  kg/m<sup>2</sup>).<sup>10</sup>

Healthcare encounters provide critical opportunities for clinicians to offer anticipatory guidance, patient education, and lifestyle counseling to individuals with obesity. This study aimed to assess the common comorbidities associated with overweight and obesity among adults attending a general outpatient clinic in Uyo, Nigeria. The findings are intended to inform clinical guidelines and public health policy.

## Materials and methods

### Study Design and Setting

This hospital-based, descriptive cross-sectional study was conducted at the General Outpatient Clinic (GOPC) of the University of Uyo Teaching Hospital (UUTH), Uyo, Akwa Ibom State, Nigeria. The clinic operates weekdays year-round, managed by consultant family physicians, their resident doctors and medical officers.

### Study Population, Sample Size determination and Sampling Technique

The study population consisted of adults (aged 18–60 years) presenting to the GOPC between July and December 2017. Using the Leslie Kish formula for cross-sectional studies and assuming a 35.1% prevalence of overweight (from a prior Nigerian

study), a minimum sample size of 350 was calculated.<sup>11,12</sup> With a 10% allowance for non-response and incomplete data, the final calculated sample size was 385.

Participants were consecutively recruited into the study after BMI screening. Those with a BMI  $\geq 25$  kg/m<sup>2</sup> were enrolled daily until the calculated sample size was reached. Exclusions included individuals with skeletal deformities affecting height measurement, critical illness, pregnancy, or conditions causing edema (e.g., ascites).

### Data Collection

Data were collected using a semi-structured questionnaire using self and interviewer administered techniques. It covered socio-demographics, lifestyle factors, and comorbidities. Anthropometric measurements (weight, height, blood pressure) and biochemical assays (fasting blood glucose, lipid profile) were performed. A pre-test of the questionnaire was carried out using 40 randomly selected respondents from the GOPD clinic of St. Luke's Hospital Anua before commencement of the study.

Weight was measured to the nearest 0.1 kg using a calibrated bathroom scale. Height was measured to the nearest 0.1 m using a standardized wooden stadiometer. Blood pressure was measured with a mercury sphygmomanometer and appropriate cuff size. Fasting blood glucose was assessed using an Accu-chek glucometer, standardized against a laboratory glucose oxidase method. Venous blood samples were analyzed for lipid profile at the hospital's chemical pathology laboratory.

### Definitions

- Overweight: BMI 25.0–29.9 kg/m<sup>2</sup>, Obesity: BMI  $\geq 30.0$  kg/m<sup>2</sup> (Class I: 30.0–34.9; Class II: 35.0–39.9; Class III:  $\geq 40$ )<sup>10</sup>.
- Hypertension: BP  $\geq 140/90$  mmHg<sup>7</sup>.
- Diabetes mellitus: Fasting blood glucose  $\geq 126$  mg/dL (7.0 mmol/L)<sup>7</sup>.
- Dyslipidemia: Total cholesterol  $\geq 200$  mg/dL (5.17 mmol/L); triglycerides  $\geq 150$  mg/dL (1.7 mmol/L); LDL-C  $\geq 100$  mg/dL (2.58 mmol/L); HDL-C  $< 40$  mg/dL (1.03 mmol/L)<sup>7</sup>.

### Data Analysis

Data were analyzed using SPSS version 17.0.

Descriptive statistics (means, standard deviations, frequencies, percentages) summarized continuous and categorical variables. Associations were tested using the chi-square test. Statistical significance was set at  $p < 0.05$ .

**Ethical Considerations**

Ethical approval was obtained from the UUTH Research and Ethics Committee. Written informed consent was obtained from all participants and participation was voluntary.

**Results**

A total of 385 questionnaires were distributed, of which 380 were returned with complete information and laboratory results, yielding a response rate of 98.2%. The age of respondents ranged from 18 to 60 years, with a mean ( $\pm$ SD) of  $40.93 \pm 9.75$  years.

**Socio-demographic Characteristics of Respondents**

The socio-demographic profile of the respondents is

**Table 1: Socio-demographic Characteristics of Respondents**

Socio-demographic characteristics	Frequency	Percentage(%)
<b>Age Group (years)</b>		
Less than 40	185	48.7
40 and above	195	51.3
<b>Gender</b>		
Males	102	26.8
Females	278	73.2
<b>Level of education</b>		
No formal education	7	1.8
Primary	44	11.6
Secondary	63	16.6
Tertiary	266	70.0
<b>Marital Status</b>		
Single	101	26.6
Married	237	62.4
Divorced	2	0.5
Widowed	33	8.7
Separated	7	1.8
<b>Religion</b>		
Christianity	377	99.2
Muslim	3	0.8
<b>Tribe</b>		
Igbos	80	21.1
Hausa	3	0.8
Yoruba	8	2.1
Ibibio	247	65.0
Others	42	11.0
<b>Residence</b>		
Urban	321	84.5
Rural	59	15.5
<b>Income Group</b>		
Less than ₦50,000	185	48.7
₦50,000 - ₦100,000	95	25.0
Above ₦100,000	100	26.3
<b>Occupation</b>		
Class1	26	6.8
Class2	175	46.1
Class3N	9	2.4
Class3M	4	1.0
Class 4	161	42.4
Class 5	5	1.3

presented in Table 1. Slightly more than half (51.3%) were aged 40 years or older. The majority were females (73.2%), had attained tertiary education (70.0%), were married (62.4%), identified as Christian (99.2%), resided in urban areas (84.5%), and were of the Ibibio tribe (65.0%). Regarding monthly income, 48.7% earned less than ₦50,000, while 26.3% earned above ₦100,000. For occupational class, the largest proportion (46.1%) belonged to Class 2 (intermediates), and the smallest to Class 3M (skilled manual; 1.0%).

**Common Comorbidities Among Respondents**

The frequencies of the assessed comorbidities are shown in Table 2. The most prevalent comorbidity was elevated LDL-cholesterol (66.3%), followed by hypertension (58.2%) and hypercholesterolemia (52.6%). The least prevalent was low HDL-cholesterol (3.9%).

**Association Between Overweight/Obesity and Comorbidities**

The relationship between BMI category (overweight versus obese) and each comorbidity is detailed in Table 3. Of all conditions assessed, only joint arthropathies/osteoarthritis showed a statistically significant association with obesity/overweight ( $\chi^2 = 4.901, p = 0.03$ ).

**Table 2: Frequency of Common Comorbidities Among Respondents**

Co-morbidities	Frequency(n=380)	Percentage(%)
<b>Hypertension</b>		
Yes	221	58.2
No	159	41.8
<b>Diabetes Mellitus</b>		
Yes	47	12.4
No	333	87.6
<b>Total cholesterol</b>		
Normal	180	47.4
Abnormal (increased)	200	52.6
<b>Triglycerides</b>		
Normal	279	73.4
Deranged(increased)	101	26.6
<b>HDL</b>		
Normal	365	96.1
Abnormal(decreased)	15	3.9
<b>LDL</b>		
Normal	128	33.7
Abnormal(increased)	252	66.3
<b>Erectile Dysfunction (n=102)</b>		
Yes	33	32.4
No	69	67.6
<b>Joint Deformities</b>		
Yes	178	46.8
No	202	53.2
<b>Infertility</b>		
Yes	115	30.3
No	265	69.7

**Table 3: Association Between Overweight/Obesity and Co-Morbidities**

Co-Morbidities	BMI Pattern		Total N=380	Statistical tests and values
	Overweight (%) n=100	Obese n (%) n=280		
<b>Blood pressure</b>				
Normal	49 (49.0)	110 (39.3)	159 (41.8)	$\chi^2= 2.85$ P=0.09
Raised	51 (51.0)	170 (60.7)	221 (58.2)	
<b>Blood Glucose</b>				
Normal	82 (82.0)	251 (89.6)	333 (87.6)	$\chi^2= 3.971$ P=0.05
Raised	18 (18.0)	29 (10.4)	47 (12.4)	
<b>Total Cholesterol</b>				
Normal	50 (50.0)	130 (46.4)	180 (47.4)	$\chi^2= 0.3770$ P=0.54
Deranged (raised)	50 (50.0)	150 (53.6)	200 (52.6)	
<b>Triglycerides</b>				
Normal	73 (73.0)	206 (73.6)	279 (73.4)	$\chi^2= 0.0123$ P=0.91
Deranged(raised)	27 (27.0)	74 (26.4)	101 (26.6)	
<b>HDL</b>				
Normal	97 (97.0)	268 (95.7)	365 (96.1)	$\chi^2= 0.321$ P=0.77
Deranged(reduced)	3 (3.0)	12 (4.3)	15 (3.9)	
<b>LDL</b>				
Normal	40 (40.0)	88 (31.4)	128 (33.7)	$\chi^2= 2.423$ P=0.12
deranged (raised)	60 (60.0)	192 (68.6)	252 (66.3)	
<b>Erectile Problems</b>				
Yes	12 (25.0)	21 (38.9)	33 (32.4)	$\chi^2= 2.44$ P=0.12
No	36 (75.0)	32 (61.1)	69 (67.6)	
<b>Joint Deformities</b>				
Yes	38 (38.0)	140 (50.0)	178 (46.8)	$\chi^2= 4.901$ P=0.03
No	62 (62.0)	135 (50.0)	202(53.2)	
<b>Infertility</b>				
No	74 (74.0)	191 (68.2)	265 (69.7)	$\chi^2= 1.168$ P=0.28
Yes	26 (26.0)	89 (31.8)	115 (30.3)	

\*Percentages for erectile dysfunction are calculated from the male subgroup (n=102; Overweight males=48, Obese males=54).

## Discussion

This study assessed the common comorbidities associated with overweight and obesity among adults attending a general outpatient clinic in Uyo, Nigeria. The most common comorbidities were dyslipidemic abnormalities (elevated LDL: 66.3%; hypercholesterolemia: 52.6%) and hypertension (58.2%). This compares favourably with results of other studies. A study by Schmiegelow and colleagues in Denmark reported that increase in BMI increases the prevalence of dyslipidaemia, hypertension, diabetes mellitus and metabolic disorder in fertile women.<sup>13</sup> Guh et al in a systematic review of articles reported in their study that overweight and obesity were associated with development of metabolic syndrome which comprises of hypertension, dyslipidemia, diabetes mellitus and abdominal obesity.<sup>14</sup> A review article by Singh and colleagues showed that dyslipidaemia was one of the co-morbidities associated with overweight and obesity.<sup>15</sup> Osuji et al conducted a study on women who came for "August meeting", a yearly women meeting in south-eastern Nigeria, and reported an association between overweight/obesity and dyslipidemia.<sup>16</sup> While the rates of dyslipidaemic abnormalities were high in this study, and consistent

with the known metabolic sequelae of obesity, they did not show a statistically significant association with BMI category in this sample. This lack of significance may be due to the use of antihypertensive and lipid-lowering medications by participants, a hospital-based sampling bias, or the relatively modest sample size.

Notably, osteoarthritis/joint arthropathies were significantly associated with overweight/obesity (p=0.03). This finding agrees with results of other studies. A study by Adebimpe and his colleagues in a study done in South Western Nigeria reported that overweight and obesity were strongly associated with an increased risk of arthritis, and the knee joint was mostly affected.<sup>17</sup> A study by Bliddal and his two colleagues reported the significance of weight loss in improving the signs and symptom of osteoarthritis, disability and function in obese patients.<sup>18</sup> Idung et al in their study in South-South Nigeria also confirmed that

osteoarthritis in addition to hypertension were the most prevalent co-morbidities associated with overweight and obesity.<sup>19</sup> These findings are biomechanically plausible, as excess body weight increases mechanical stress on weight-bearing joints, accelerating cartilage degeneration.<sup>10,11</sup> It is also clinically significant in this population, given the high proportion of older adults and individuals in occupational classes involving physical work (Classes 2 & 4), which may exacerbate joint symptoms.

Contrary to several literatures,<sup>14,20-24</sup> neither diabetes mellitus nor erectile dysfunction showed a significant statistical association with overweight and obesity. The lower-than-expected proportion of diabetes mellitus may be influenced by ongoing management in this clinical population. The non-significant finding for erectile dysfunction may stem from underreporting due to social stigma or the smaller male subsample.

A key strength of this study is its integration of clinical measurements with laboratory data. However, limitations include its hospital-based, cross-sectional design, which precludes causal inference, and the use of consecutive sampling, which may affect generalizability. The potential for

underreporting of sensitive conditions (e.g., erectile dysfunction, infertility) and the influence of existing treatments on blood pressure and lipids must also be considered.

### Conclusion and Recommendation

This study identified osteoarthritis as the most significant comorbidity associated with overweight and obesity in this clinical population. While dyslipidemia and hypertension were highly prevalent, their lack of statistical association highlights the complex interplay of treatment and measurement in clinical studies. The findings underscore the need for integrated clinic-based interventions that combine weight management with musculoskeletal health. Public health strategies should promote lifestyle modifications targeting dietary patterns and physical activity to mitigate the burden of obesity-related comorbidities.

**Source of funding:** This study was funded by the lead author

**Conflict of interest:** None

**Author Contributions:** The lead author conceived the work and all authors were involved in critically reviewing, writing and reading through the final manuscript.

### References

1. Saunders KH, Igel L.I, Fink S. Nutrition, Nutritional Disorders & Obesity: In Mcphee SJ, Papadalis MA, Rabow MW, Maxine A, Tierney LM, (editors). Current medical Diagnosis and Treatment. 64th ed. New York : Lange medical Books: 2025:p1235- 1254.
2. World Health Organization. Obesity and overweight (internet), Geneva, Switzerland: World Health Organization 2025. Available at <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>. Accessed on May 7 2025.
3. Bluher M. An overview of Obesity-related complications: The Epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes. Diabetes Obes Metab. 2025; 27(2):3-19.
4. Chukwuonye II, Chuku A, John C, Ohagwu KA, Imoh ME, Isa SE et al. Prevalence of overweight and obesity in adult Nigerians- a systematic review. Diabetes Metab Syndr Obes. 2013; 6:43-47.
5. Boutari C, Mantzoros CS. A 2022 update on epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022; 133:155217
6. National Heart, Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report [Internet]. Bethesda (MD): NIH; 1998 Sep [updated 2013]. Available from: [https://www.nhlbi.nih.gov/guidelines/obesity/ob\\_gdlns.pdf](https://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf) Accessed September 4 2025.
7. Rezaianzadeh A, Namayandeh SM, Sadr SM. National Cholesterol Education Program Adult Treatment Panel III versus International Diabetic Federation definition of metabolic syndrome, which one is associated with diabetes mellitus and coronary artery disease? Int J Prev Med. 2012;3(8):552-8.
8. Peltz G, Aguirre MT, Sanderson M, Fadden MK. The role of fat mass index in determining obesity. Am J Hum Biol. 2010;22(5):639-47. DOI: 10.1002/ajhb.21056
9. Iloh GUP, Amadi AN, Nwankwo BO, Ugwu VC. Obesity in adult Nigerians: a study of its pattern and common primary co-morbidities in a rural mission general hospital in Imo State, south-eastern Nigeria. Niger J Clin Pract. 2011;14(2):212-8. DOI: 10.4103/1119-3077.84021
10. Siminialayi IM, Emem-Chioma PC, Dapper DV. The prevalence of obesity as indicated by BMI and waist circumference among Nigerian adults attending family medicine clinics as outpatients in Rivers State. Niger J Med. 2008;17(3):340-5.
11. Araoye MO. Sample size estimation. In: Araoye MO, editor. Research methodology with statistics for health and social sciences. 1st ed. Ilorin: Nathadex Publishers; 2004. P. 115-22.
12. Desalu OO, Salami AK, Oluboyo PO, Olarinoye

- JK. Prevalence and socio-demographic determinants of obesity among adults in an urban Nigerian population. *Sahel Med J.* 2008;11(2):61-4.
13. Schmiegelow MD, Andersson C, Kober L, Andersen SS, Norgaard ML, Jensen TB et al. Associations Between Body Mass Index and Development of Metabolic Disorders in Fertile Women- A Nationwide Cohort Study. *JAHA.*2014;3:e000672.
14. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of comorbidities related to obesity and overweight: A systematic review and meta-analysis. *BMC Public Health.*2009; 9:88.
15. Singh AK, Singh SK, Agrawal N, Gopal K. Obesity and dyslipidemia. *Int J Biol Med Res.*2011;2(3):824-828.
16. Osuji CU, Nzerem BA, Meludu S, Dioka CE, Nwobodo E, Amilo GI. The prevalence of overweight and obesity and dyslipidemia amongst a group of women attending August meeting. *Niger Med J.* 2010;51:155-159.
17. Adebimpe WO, Omobuwa O, Omisore A, Adeoye O. Obesity indices as predictors of pattern of self reported arthritis among elderly women in Southwestern Nigeria. *SAGE Open Med.* 2015;3:2050312115572039.
18. Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: evidence hypotheses and horizons-a scoping review. *Obes Rev.*2014;15(7):587-586.
19. Idung AU, Abasiubong F, Udoh SB, Ekanem US. Overweight and obesity profiles in Niger Delta Region, Nigeria. *Afr J Prim Health Care Fam Med.*2014;6(1):542.
20. Pantalone KM, Hobbs TM, Chagin KM, Kong SX, Wells BJ, Kattan MW et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. *BMJ Open.* 2017;7:11.
21. Adam VY, Isah JA. Prevalence and comorbidities of childhood overweight and obesity among school aged children in an urban settlement in Benin city, Nigeria. *Niger J Paediatr.* 2017;44(1):7-13
22. Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: Androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. *The FBBS J.*2009; 276: 50.
23. Skrypnik D, Bogdanski P, Musialik K, Lekarski PM. Obesity –significant risk factor for erectile dysfunction in men. *Pubmed.* 2014; 36(212):137-141.
24. Oyelade BO, Jemilohun AC, Aderibigbe SA. Prevalence of erectile dysfunction and possible risk factors among men of South- Western Nigeria: a population based study. *Pan Afr Med J.* 2016; 24:124.